Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial

The Lancet. Diabetes & Endocrinology
Hiddo J L HeerspinkDick de Zeeuw

Abstract

The primary results of the ALTITUDE trial showed no benefit of aliskiren on renal outcomes (doubling of serum creatinine and end-stage renal disease) when used as an adjunct to angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in patients with type 2 diabetes and chronic kidney disease or cardiovascular disease. We did a prespecified analysis of the ALTITUDE trial to analyse the effects of aliskiren on surrogate renal outcomes in all patients and on primary renal outcomes in subgroups of patients. In the double-blind, randomised, controlled ALTITUDE trial, 8561 patients with type 2 diabetes and chronic kidney disease or cardiovascular disease were randomly assigned (1:1) to receive aliskiren 300 mg per day or placebo as an adjunct to ACE inhibitors or ARBs. Randomisation was stratified on the basis of baseline urinary albumin-to-creatinine ratio and presence of cardiovascular disease history, and treatment assignments were masked to all patients and study staff. Patients were followed up for a median of 2·6 years (IQR 2·0-3·2). In our secondary analysis, we investigated prespecified intermediate renal outcomes of transitions in albuminuria stages (ie, transitions between normoalbuminuria, mi...Continue Reading

References

Sep 5, 2001·Kidney International·T H JafarUNKNOWN AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Disease
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
May 20, 2003·Kidney International·Piero RuggenentiUNKNOWN GISEN Group Investigators
Jul 16, 2003·The American Journal of the Medical Sciences·Ursula C BrewsterMark A Perazella
Sep 1, 1957·The Journal of Experimental Medicine·L T SKEGGSN P SHUMWAY
Nov 2, 2004·The New England Journal of Medicine·Piero RuggenentiUNKNOWN Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators
Aug 16, 2006·Annals of Internal Medicine·Andrew S LeveyUNKNOWN Chronic Kidney Disease Epidemiology Collaboration
Mar 29, 2007·Diabetes Care·Hirofumi MakinoUNKNOWN INNOVATION Study Group
Jun 6, 2008·The New England Journal of Medicine·Hans-Henrik ParvingUNKNOWN AVOID Study Investigators
Jan 16, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Hans-Henrik ParvingMarc A Pfeffer
Feb 20, 2009·Journal of the American Society of Nephrology : JASN·Bastiaan E de GalanUNKNOWN ADVANCE Collaborative Group
May 16, 2009·Journal of the American Society of Nephrology : JASN·Toshiharu NinomiyaUNKNOWN ADVANCE Collaborative Group
Mar 11, 2011·The New England Journal of Medicine·Hermann HallerUNKNOWN ROADMAP Trial Investigators
Nov 6, 2012·The New England Journal of Medicine·Hans-Henrik ParvingUNKNOWN ALTITUDE Investigators
Mar 27, 2013·Nature Reviews. Endocrinology·Hiddo J Lambers Heerspink, Dick de Zeeuw
Nov 12, 2013·The New England Journal of Medicine·Linda F FriedUNKNOWN VA NEPHRON-D Investigators
Apr 25, 2014·Kidney International·Sara S RoscioniDick de Zeeuw
Apr 19, 2015·Clinical Journal of the American Society of Nephrology : CJASN·Linda F Fried, Julia Lewis
Apr 19, 2015·Clinical Journal of the American Society of Nephrology : CJASN·Hiddo J Lambers Heerspink, Ron T Gansevoort
May 7, 2015·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Morgan E GramsUNKNOWN CKD Prognosis Consortium

❮ Previous
Next ❯

Citations

Jan 18, 2016·The Lancet. Diabetes & Endocrinology·Martin GallagherVlado Perkovic
Jan 18, 2017·Journal of Diabetes Investigation·Yosuke HirakawaMasaomi Nangaku
Jan 18, 2018·Clinical Journal of the American Society of Nephrology : CJASN·Katherine G GarloDavid M Charytan
Mar 11, 2017·Clinical Journal of the American Society of Nephrology : CJASN·Simit M Doshi, Allon N Friedman
Feb 28, 2020·The Cochrane Database of Systematic Reviews·Meaghan LunneyPietro Ravani
Nov 5, 2019·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Nida Siddiqi, Ibrahim F Shatat
Mar 13, 2021·Frontiers in Medicine·Amir ShabakaGema Fernandez-Juarez
Mar 24, 2021·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Elias SanidasJohn Barbetseas
Jul 31, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Junmin WangGuang Ji
Aug 7, 2021·Advanced Drug Delivery Reviews·Huan XuLeaf Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.